Objective: Postthyroidectomy radioiodine (RAI) therapy is indicated for papillary thyroid
carcinoma (PTC) with high-risk features. There is variability in the timing of RAI therapy with …

Objective It remains unclear whether the time interval between total thyroidectomy and
radioactive iodine therapy (RAIT) affects clinical outcomes in papillary thyroid carcinoma …

There is no consensus regarding the timing of adjuvant radioactive iodine therapy (RAI)
therapy in low-and intermediate-risk papillary thyroid carcinoma (PTC). We analyzed the …

Objective The utility of radioiodine (RAI) therapy in intermediate‐risk papillary thyroid
carcinoma (PTC) remains a topic of ongoing discussion. This systematic review and meta …

Context Current guidelines recommend a selective use of radioiodine treatment (RAI) for
papillary thyroid cancer (PTC). Objective This work aimed to determine how policy changes …

Context: Papillary thyroid cancer (PTC) is the most common endocrine malignancy. The long-
term prognosis is generally excellent. Due to a paucity of data, debate exists regarding the …

Objective To describe the outcomes with the selective use of radioactive iodine (RAI) in
patients who are at intermediate risk of death from papillary thyroid cancer, focusing on 2 …

Background Papillary thyroid cancer (PTC) is a common endocrine malignancy with
relatively good prognosis. Radioactive iodine (RAI) is considered effective for patients with …

It remains controversial whether papillary thyroid cancer (PTC) patients with low-to
intermediate-risk disease should receive radioactive iodine (RAI) after total thyroidectomy …

Background The beneficial effects of radioactive iodine (RAI) ablation for intermediate-risk
papillary thyroid cancer (PTC) patients are still controversial. Materials and methods To …